VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
Portfolio Pulse from
VYNE Therapeutics Inc. reported a Q3 loss of $0.29 per share, which was larger than the Zacks Consensus Estimate of a $0.24 loss. However, the company topped revenue estimates.
November 07, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
VYNE Therapeutics reported a Q3 loss of $0.29 per share, missing the Zacks Consensus Estimate of a $0.24 loss. Despite this, the company exceeded revenue expectations.
The larger-than-expected loss per share is a negative indicator, but the fact that VYNE exceeded revenue expectations could offset some of the negative sentiment. This mixed result may lead to neutral short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100